Bladder Cancer Academy 2017: Immunotherapy of Advanced Bladder Cancer: The Next Frontier – UroToday
|
Bladder Cancer Academy 2017: Immunotherapy of Advanced Bladder Cancer: The Next Frontier
UroToday Summarizing the recent immunotherapy trial results, the ICPI are active and well tolerated and have transformed bladder cancer therapy with the most important advancement in over 30 years. The FDA has approved 5 ICPI as 2nd line chemotherapy. |
